Is BrightSpring BTSG Stock Expensive at 24.5x Forward P/E?

Key Takeaways BrightSpring posted Q4 revenue of $3.55B, up 29.3%, with adjusted EBITDA rising 40.7%.BTSG guides 2026 EBITDA growth of 23%-28%, outpacing revenue growth of 11.9%-16.2%.BrightSpring faces ~$600M revenue headwinds from IRA impacts and generic drug conversions.BrightSpring Health Services, Inc. (BTSG) is coming off a strong finish to 2025, and the market is rewarding that momentum. The stock now trades at 24.5 times forward 12-month earnings per share, raising the key question for investors: is ...